



Patent Application  
Attorney Docket No. 101.02

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE MAR 26 2002

IN RE APPLICATION OF: MORSEY, ET AL.

TECH CENTER 1600/2900

APPLICATION NO.: 09/938,700

: Examiner:

FILING DATE: AUGUST 24, 2001

: Group Art Unit 1646

TITLE: ANTI-IgE VACCINES

MAR 26 2002

Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: March 19, 2002

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 573-2030

Lorraine B. Ling  
Lorraine B. Ling  
Attorney for Applicant(s)  
Reg. No. 35,251

Express Mail No. EL 874868210 US